---
layout: post
date: 2026-01-22
title: "[ë…¼ë¬¸ë¦¬ë·°] Distinct neuroimaging subtypes of ADHD among adolescents based on semi-supervised learning"
tags: [ADHD, GAN]
categories: [Paper Review]
---


## Abstract

- ADHDëŠ” ì†Œì•„ê¸°ì— ë°œë³‘í•˜ëŠ” neurodevelopmental disorder(ì‹ ê²½ ë°œë‹¬ ì¥ì• )ë¡œ, ì§„ë‹¨ê³¼ ì•„í˜• ë¶„ë¥˜ê°€ ì„ìƒì  íŠ¹ì„±ì— ê¸°ë°˜í•´ ì£¼ê´€ì ì´ë©° ì‹ ë¢°ì„± ë¶€ì¡±.
- ì„ìƒì  subtype ë¶„ë¥˜ëŠ” ì˜ˆí›„ì— ëŒ€í•œ ëª…í™•í•œ ì§€í‘œ ì œê³µ X

_â†’ __**Semi-Supervised Learning**__ ê¸°ë°˜ì˜ heterogenity íŒŒì•… method ì œì‹œ_

- Adolescent Brian Cognitive Development (ABCD) ë°ì´í„° í™œìš©
- ì •ìƒêµ° ëŒ€ë¹„ Cortical Thicknessë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì„¸ ê°€ì§€ subtype í™•ì¸ â†’ ì €ë°œë‹¬(lower CT)/ê³¼ë°œë‹¬(higher CT)/í˜¼í•©
	- `ì €ë°œë‹¬êµ°` : cognitive score ìœ ì˜ë¯¸í•˜ê²Œ ë‚®ê³  ì‚¬íšŒê²½ì œì  ì§€ìœ„ ì¢‹ì§€ ì•ŠìŒ
	- `ê³ ë°œë‹¬êµ°` : ê°ì„±ì œ ì•½ë¬¼(stimulant medication) ë°˜ì‘ ì•ˆì¢‹ìŒ
- Gene expressions / Neurotransmitter distributions (ìœ ì „ì ë°œí˜„ / ì‹ ê²½ ì „ë‹¬ ë¬¼ì§ˆ ë¶„í¬)
	- `ì €ë°œë‹¬/í˜¼í•©êµ°` : ë„íŒŒë¯¼ ë° í¥ë¶„ì„± ê²½ë¡œì˜ upregulation(ìƒí–¥ ì¡°ì ˆ) ê°•í•¨

		> ğŸ’¡ **Upregulation** : íŠ¹ì • ì‹ í˜¸/ìê·¹ì— ë°˜ì‘í•´ ì„¸í¬ ë‚´ íŠ¹ì • ë¬¼ì§ˆ(ìˆ˜ìš©ì²´, ë‹¨ë°±ì§ˆ ë“±)/ë°œí˜„ ì¦ê°€í•˜ëŠ” í˜„ìƒ


			_â†’ ì‹ í˜¸/ìê·¹ì— ëŒ€í•œ ë¯¼ê°ì„±ì„ ë†’ì´ê¸° ìœ„í•œ ë°˜ì‘_

	- `ê³ ë°œë‹¬êµ°` : ì•½í•¨

	_â†’ ê°ì„±ì œ ì•½ë¬¼ì— ëŒ€í•œ ë°˜ì‘ì„± ì°¨ì´ ì„¤ëª… ê°€ëŠ¥ (ê³ ë°œë‹¬êµ°ì—ì„œ í¥ë¶„ì„± ê²½ë¡œì˜ upregulation ì•½í•¨, ì €ë°œë‹¬/í˜¼í•©êµ°ì—ì„œ ë†’ìŒ)_


---


---



## Introduction


DSM-5(Diagnostic and Statistical Manual of Mental Disorder, fifth edition)ì— ë”°ë¥´ë©´ ADHDëŠ” ì„¸ ê°€ì§€ì˜ ì„ìƒ í‘œí˜„í˜•ìœ¼ë¡œ ë‚˜ë‰¨

- `Redominantly inattentive (ADHD-I)` : ì£¼ì˜ë ¥ ê²°í•
- `Predominantly hyperactive/impulsive (ADHD-H/I)` : ê³¼ì‰ í–‰ë™/ì¶©ë™ì„±
- `Combined (ADHD-C) presentations` : ë³µí•©í˜•

_â†’ ì„ìƒ ì¦ìƒì„ ì´ìš©í•œ ë¶„ë¥˜ëŠ” ì˜ˆí›„ì™€ ê´€ë ¨ì„± ë‚®ìŒ_


<span class="notion-red">_â†’ ë‚®ì€ ê°•ê±´ì„±, ì•½ë¬¼ ë°˜ì‘ êµ¬ë³„ ë¶ˆê°€, ë™ë°˜ ì§ˆí™˜, ê³µìœ ë˜ëŠ” neuropsychological(ì‹ ê²½ì‹¬ë¦¬í•™ì ) ê²°ì†, ì‹ ê²½ìƒë¬¼í•™ì  ê¸°ì € ë°˜ì˜ ë¶ˆê°€ ë¬¸ì œ_</span>


MRIë¥¼ ì´ìš©í•œ ì—°êµ¬ë“¤ì´ ì§„í–‰ë˜ì–´ ì™”ìœ¼ë‚˜ ì¼ê´€ì„± ì—†ëŠ” ê²°ê³¼ë¥¼ ë³´ì„

- ê¸°ì¡´ ì—°êµ¬ë“¤ì€ hierarchical clustering, K-means, Bayesian ê°™ì€ unsupervised clustering ìœ„ì£¼

	â†’ í™˜ì ë°ì´í„°ì—ë§Œ ì˜ì¡´í•´ clustering


_**â‡’ Semi-supervised learningì„ ì´ìš©í•´ ì •ìƒêµ° ê³ ë ¤**_

	- Smile-GAN ì°¨ìš© _(Yang et al., 2021)_
	- data distributionê³¼ data transformì˜ linearity ê°€ì •ì— ì˜ì¡´í•˜ì§€ ì•ŠìŒ

		> ğŸ’¡ **Not rely on Assumptions?**

			- ì…ë ¥ ë°ì´í„°ë“¤ì´ Gaussian distributionê³¼ ê°™ì€ íŠ¹ì • ë¶„í¬ë¥¼ ë”°ë¥¸ë‹¤ê³  ê°€ì •í•˜ì§€ ì•ŠìŒ
			- í™˜ì ë°ì´í„°ê°€ ì •ìƒì—ì„œì˜ ì„ í˜• ë³€í™˜(NC + noise)ìœ¼ë¡œ ê°€ì •í•˜ì§€ ì•ŠìŒ

		<span class="notion-red">_**â†’ Smile-GANì€ data ìì²´ì˜ **_</span><span class="notion-red">_**ë¹„ì„ í˜• êµ¬ì¡°**_</span><span class="notion-red">_**ë¥¼ í•™ìŠµ**_</span>


**ì—°êµ¬ ë‚´ìš©**

- Smile-GANì„ ì´ìš©í•´ ABCD cohortì— ëŒ€í•´ Cortical Thickness ë¶„ì„
	- Subtype ë¶„ë¥˜
	- ì„ìƒ ë°œí˜„/í™˜ê²½ ìš”ì¸/ì¹˜ë£Œ ë°˜ì‘ ì¡°ì‚¬
- ì™¸ë¶€ ë°ì´í„°ì…‹ì— subtype ì ìš©/ê²€ì¦

---


---



## Materials and Method



### Materials



#### Participants


DSM-5 ê¸°ë°˜ ì§„ë‹¨, _Kiddie-Schedule of Affective Disorders and Schizophrenia for DSM-5 (KSADS-COMP) â†’ ì¸í„°ë·° ê¸°ë°˜ì˜ ADHD ì¦ìƒ ìˆ˜ì¹˜(ê°œìˆ˜)_

- Schizophrenia(ì •ì‹ ë¶„ì—´ì¦), bipolar disorder(ì–‘ê·¹ì„± ì¥ì• ), ì¶”ì • IQ < 70 ì œì™¸

**ABCD**

- `Baseline` : ADHD/HC, 929/5580
	- age 9.83 Â± 0.50 years, 68.7% male for ADHD
	- age 9.97 Â± 0.62 years, 52.0% male for HC
- `2 year(follow-up)` : 633/4219
	- age 11.96 Â± 0.58 years, 69.8% male for ADHD
	- age 11.90 Â± 0.59 years, 53.2% male for HC

**ADHD-200 (external)**

- `Baseline` : 330/414
	- age 11.67 Â± 3.02, 78.2% male for ADHD
	- age 11.67 Â± 2.89 years, 53.0% male for HC

---



#### Image pre-processing and quality control


**ABCD**

- FreeSurfer ì´ìš©í•œ cortical reconstruction, segmentation pipeline ìˆ˜í–‰

	_â†’ DAIRCì—ì„œ ì œê³µí•œ ì „ì²˜ë¦¬ëœ íŒŒì¼ ì‚¬ìš©_

- Destrieux template ì ìš©
- Neuro-Combat ì´ìš©í•œ site-specific variations estimation/regression

	> ğŸ’¡ **Site-specific variations estimation/regression?**

		- ì¥ë¹„/ìŠ¤ìº” site ì°¨ì´ë¡œ ì¸í•œ í¸ì°¨(site effect)ë¥¼ ì¶”ì •í•´(estimation) ì œê±°/ì¡°ì •(harmonization)

**ADHD-200**

- NITRC ì´ìš©í•œ ìœ ì‚¬ ê³¼ì • ìˆ˜í–‰
- Destrieux template ì ìš©, parcellate the brain into 148 ROIs

---



### Analysis



#### Semi-supervised classification


**Smile-GAN**

- nonlinear semi-supervised DL algorithm
- GAN ì´ìš©í•œ ì •ìƒê°’ìœ¼ë¡œë¶€í„° í™˜ì ë°ì´í„° í•©ì„±
- Adversarial learningì„ í†µí•œ í•©ì„±/ì‹¤ì œ ë°ì´í„° êµ¬ë³„ ë¶ˆê°€í•˜ë„ë¡ í•¨

**Input**

- `HC` : í‰ê·  1, í‘œì¤€ í¸ì°¨ 0.1ë¡œ ì •ê·œí™”
- `ADHD` : HCì— ëŒ€í•´ Z-score normalize (HC ê·¸ë£¹ì˜ í‰ê· /í‘œì¤€ í¸ì°¨ ì´ìš©)

**Subtype ìˆ˜ ê²°ì •**

- Adjusted Random Indexì™€ permutation test ì§„í–‰
- 2-7ê°œì˜ cluster ë¶„í• ì— ëŒ€í•´ ê°ê° 5-fold cross-validation ìˆ˜í–‰

<span class="notion-red">_â†’ 3ê°œ clusterì— ëŒ€í•´ì„œë§Œ p-value < 0.05 ë¡œ ìœ ì˜ë¯¸_</span>


_ë¶„ì„ ê²°ê³¼ ê²€ì¦ì„ ìœ„í•´ ê° subtypeì—ì„œ main resultì™€ validation datasetê°„ì˜ T-score spatial correlationì„ ì¡°ì‚¬_


(Main result : ABCD; validation dataset : ADHD-200)


---



#### Imaging-transcriptome analysis


Subtypeì˜ genetic signature ë¶„ì„ì„ ìœ„í•´ Allen Human Brain Atlas (AHBA) microarray dataset ì‚¬ìš©

- 6ê°œ sampleì˜ left hemisphere transcriptome data ì‚¬ìš©
- í‘œì¤€ ì „ì²˜ë¦¬ ìˆ˜í–‰ (probe-to-gene annotation ì‹ë³„/filtering/brain region assign/scaled robust sigmoid transformation) 

	â†’ Destrieux template êµì°¨ í›„ 72ê°œ ROIì— ëŒ€í•´ 10,027 gene expression íšë“

- RNA expressionê³¼ T stastics ê°„ì˜ correlation ë¶„ì„

_â†’ ê° Subtypeê³¼ ë†’ì€ correlation ë³´ì´ëŠ” gene ì‹ë³„_


---



#### Imaging-neurochemical analysis

- 3ê°€ì§€ì˜ neurotransmitter systemì— ê±¸ì¹œ 5ê°œì˜ receptor ë¶„ì„ (JuSpace ì´ìš©)
- Neurochemical density mapì€ prior PET/SPECT ì—°êµ¬ì—ì„œ ì°¨ìš©
	- MNI templateì— ì •ë ¬ë˜ì–´ Destrieux atlas ë”°ë¼ 148ê°œ ROIë¡œ ë¶„í• 
- Neurochemical density mapê³¼ subtypeì˜ T stastics mapì˜ spatial correlation ë¶„ì„

<span class="notion-red">_â†’ Subtype ë³„ neurochemical pattern ë¶„ì„_</span>


---



### Statistical analysis

- Subtype ë¶„ì„ ì „ follow-up ë°ì´í„°ì— ëŒ€í•´ ê³µë³€ëŸ‰ ì œì–´ (age, sex, site, race, ethnicity, socioeconomic status, and birth maternal conditions)
	- ADHD-200ì˜ ê²½ìš° age, sex, site ë§Œ í†µì œ
- Smile-GAN ì´ìš©í•œ subtyping í›„ two-sample T-test
	- psychopathology(ì •ì‹ ë³‘ë¦¬), disease-related symdromes(ê´€ë ¨ ì¦í›„êµ°), and socioeconomic status(ì‚¬íšŒê²½ì œì  ì§€ìœ„) ë¹„êµ
- Disease treatment ë°˜ì‘ ë¹„êµ ìœ„í•´ baseline ë¶€í„° follow-up ê¹Œì§€ì˜ ì§„ë‹¨ëª… ë³€í™”ë¥¼ T-test ì´ìš©í•´ ë¶„ì„

---


---



## Result



#### Distinct neuroimaging subtypes of ADHD


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/ad4df74c-7cbe-4465-ac72-71345219e411/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB466Z4K3U7JD%2F20260201%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260201T041707Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQCxYPlS0G3aPdKxphuTwH8%2BAp0YXctH1lUjwYBDPHqXZAIhAOriVf%2FLudmz%2B7GAFgIcGZSiO2u4QMXIp5ta9wnHe1sKKogECMT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNjM3NDIzMTgzODA1Igwe90OHDP28bnEu5NQq3ANLVuhGGWqcjLBhf6z26IlZdDDshj8x9lGcEolY1Rxh4ZX5%2F3N297NjAyrtpn5SXy6ERtdE6CX79WXEWHpXMnyGzBSY6fILdYqIMmg0joDa1iuAEzcEKcLnGaV8xrwiYjiqHMTKmwIBG6H%2Bqufkz42YBC2hY1viNNO1S0gwu789VcJYFFPpnBINdhuN1vs%2FyPNojdjBUJ6uKpPiHLOs4OaXgLKVllcyskCtV%2Fl346uIw22ROkY7pPms95uviIe%2BieiFc2Uy209D8KVsY4d2F04qY2WdD%2FgWx3IL%2BoOOfYOpD8BjDAMrWv%2BMCk6L21eOoZKl6VRhjKti2x94697krMkZn87BKxlyBbBhiicLJJ5IPFtka4XsGollMga%2BUVp30Wi7ld2UWoUyH7PJ064dDw0IHc7JZfYQf1EiQD%2FdD6yMPTwYe%2B7TGM2IDSv%2F8A5Yc163vN0xd23KEBg2l8WMDXZ7GVIqk3WPVXx%2Bow6c3UMP4wx3fW4eNR9SD0U6a%2BejNLEjTaf15P3XqQiApifMVbRMHq6%2Fc4wg%2BC4UN%2FDYo%2F%2FeI1AgGYLfPpp5HTzLnYW9e%2F2U1BDUZpvtqiGzX4Urac101tx%2FRWtHMh4kbSwQ9X5sOnle32QHkU0c%2FJl50TDRg%2FvLBjqkAaF%2BOiDo%2BJId51DSPAaanhDSDe%2BigqhQKTDxygMVp0v4jtf%2F7%2B4YL2W6tp%2FFmoCD7gK2XG2rMuyMYdnffog4uAAtfJ6uMvxdlBP2n2XklPB23nD6%2BXaUxErgbrxoLMWn6LMd3kEnH6F7G%2Bey6RCnbvIXjif1qdwipuAfLyYxw2USqISvyOwz8%2F0Os3M6bFrHZdwxnvovIsTQezX5aKkGKwSIdUI7&X-Amz-Signature=06992c46de472c02cbf8a0c87c60604efad6f627494903c53839bdbd9ff9901f&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Cortical thicknessë¥¼ ì…ë ¥ìœ¼ë¡œ 3ê°€ì§€ Subtypeë¡œ ë¶„í• 

- `Under-developed(Lower CT)` : posterior regionì— ë‚®ì€ CT ë³´ì„
- `Over-developed(High CT)` : posterior regionì— ë†’ì€ CT ë³´ì„
- `Mixed subtype` : dorsal, prefrontal, posterior regionì— ë†’ì€ CT, temporalì—ëŠ” ë‚®ì€ CT ë³´ì„

_â†’ ë…ë¦½ ë°ì´í„°ì¸ ADHD-200ì—ì„œë„ ì¼ê´€ì ì¸ ê²°ê³¼ ë³´ì„_


---



#### Neuroimaging subtypes encompassed differential clinical, family, and social characteristics


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/1a1d4829-9137-4ff7-8c14-b80f0100c690/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB466Z4K3U7JD%2F20260201%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260201T041707Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQCxYPlS0G3aPdKxphuTwH8%2BAp0YXctH1lUjwYBDPHqXZAIhAOriVf%2FLudmz%2B7GAFgIcGZSiO2u4QMXIp5ta9wnHe1sKKogECMT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNjM3NDIzMTgzODA1Igwe90OHDP28bnEu5NQq3ANLVuhGGWqcjLBhf6z26IlZdDDshj8x9lGcEolY1Rxh4ZX5%2F3N297NjAyrtpn5SXy6ERtdE6CX79WXEWHpXMnyGzBSY6fILdYqIMmg0joDa1iuAEzcEKcLnGaV8xrwiYjiqHMTKmwIBG6H%2Bqufkz42YBC2hY1viNNO1S0gwu789VcJYFFPpnBINdhuN1vs%2FyPNojdjBUJ6uKpPiHLOs4OaXgLKVllcyskCtV%2Fl346uIw22ROkY7pPms95uviIe%2BieiFc2Uy209D8KVsY4d2F04qY2WdD%2FgWx3IL%2BoOOfYOpD8BjDAMrWv%2BMCk6L21eOoZKl6VRhjKti2x94697krMkZn87BKxlyBbBhiicLJJ5IPFtka4XsGollMga%2BUVp30Wi7ld2UWoUyH7PJ064dDw0IHc7JZfYQf1EiQD%2FdD6yMPTwYe%2B7TGM2IDSv%2F8A5Yc163vN0xd23KEBg2l8WMDXZ7GVIqk3WPVXx%2Bow6c3UMP4wx3fW4eNR9SD0U6a%2BejNLEjTaf15P3XqQiApifMVbRMHq6%2Fc4wg%2BC4UN%2FDYo%2F%2FeI1AgGYLfPpp5HTzLnYW9e%2F2U1BDUZpvtqiGzX4Urac101tx%2FRWtHMh4kbSwQ9X5sOnle32QHkU0c%2FJl50TDRg%2FvLBjqkAaF%2BOiDo%2BJId51DSPAaanhDSDe%2BigqhQKTDxygMVp0v4jtf%2F7%2B4YL2W6tp%2FFmoCD7gK2XG2rMuyMYdnffog4uAAtfJ6uMvxdlBP2n2XklPB23nD6%2BXaUxErgbrxoLMWn6LMd3kEnH6F7G%2Bey6RCnbvIXjif1qdwipuAfLyYxw2USqISvyOwz8%2F0Os3M6bFrHZdwxnvovIsTQezX5aKkGKwSIdUI7&X-Amz-Signature=29e89325d1a3838337f83f2210ce78a49d0177628d902b0f508bc6c91aa0c2f1&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Subtypeê³¼ ì„ìƒì  ê´€ì°°ì˜ ê´€ë ¨ì„± ì¡°ì‚¬ â†’ cognitive function, social behavior ì°¨ì´ ë³´ì„

- `Socioeconomic status` 
	- `Under-developed` : ë‚®ì€ ê°€ê³„ ìˆ˜ì…, ë¶€ëª¨ êµìœ¡ ìˆ˜ì¤€, ì´ë¥¸ ì‚°ëª¨ ì¶œì‚° ì—°ë ¹ / ë‹¤ë¥¸ subtype ëŒ€ë¹„ ë‚®ì€ psychopathologyì™€ cognition ìˆ˜ì¤€ ë³´ì„

<span class="notion-red">_â†’ ì¶”ê°€ë¡œ Neuroimaging subtypeê³¼ symptom-based subtypeì˜ ì—°ê´€ì„± ë¶„ì„í–ˆìœ¼ë‚˜ ê´€ë ¨ì„± íŒŒì•… ëª»í•¨_</span>


---



#### Differential response to stimulant medication among subtypes


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/310413de-9325-4f0f-929a-09869ea77609/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB46666ZOA5GQ%2F20260201%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260201T041708Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDwVa7jq6WgAwh%2FulpS2Pe5srACBRxhCmgfxdHD%2BpEZuAIhAMLYaYPMLXCGH42PAfqjuJ8vcQuaE%2Bj%2BDwxe6v%2Bkx%2BCjKogECMT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNjM3NDIzMTgzODA1IgzV7hATj1m9vrvzzQgq3AOM%2Bz%2BQp9sBw5pZeElxqRx44prKCTRvI1k6l61TE8EJ7K0Tb2yyV2nSfyn4Dfgkb52sbTpV5Ucw0j2iJgFlL%2F0rNrOVeOMoBATEabEPb8P9yHEshXcAiFusfE819Ij%2FV4D1u3xHDuYcMuxrES%2FSDCpyp1VG8UzPLtFAkILx9FKqA1c9ueWG8CB6QQ5OPEyZP08jhlqvi9rSUzEZTiwMGa1b0U%2FU%2BL7VN8uy7BOD7Muehvm1oHiZ968sj%2FpVLeWgVHGPyAl3P211lbED%2FdI18F%2BgXr%2BDrXYkA6IX47pBS9mewEQKAY4SXt6BMlagLTOdkG8DNXHp7J11rV32DzvxcwLlw0MbsIdzUlE9yiqDmtamDtzl3URayPsd08Hihj1pTyE68EYGB9tBGUZbK%2BN7yOh%2FWPaqLeWT30xgIeRe6AfrHoMKZj4jsrKCICJkY4TI3cbTHtL57b4maANdUy3BU%2FC7P4iYQrMnDsL%2FexbCybmBYqf567oGPEGVrYcZBv27H7wtyCaw30jlP4Cbcrm%2BbmivdnadIDKOR%2BboVZKgpQmaK6U4RXfRS1HPP%2Fk%2Bx%2B3%2B3qcuKY%2BE7WyLZa%2BSZZ%2FUJK9IC4mcfOgQLtcZ5q7mf2%2FLeskfJk1hwF382DPkNDCHg%2FvLBjqkARk1v%2BkN665IbIAXS6pfY6uhrPy5mqJ6R6LQx5oWZRzUboraxhPHDzndus3BiX8kUyM1Z1I64IlYiIXVO9CKE3GOBp0F1bqXIlU2qjYtpELUo5tzdwO0c1wGwWoxUb8Old%2FAAWlfto3bJ0UoPUm4mHa5PuZe%2FYEgkf76XYEhNHCX0dGAcTUj%2Fl8D%2BRt8qrJB6HuVIWOcDreAeSi29dgu1wa0%2BMte&X-Amz-Signature=9c10bf8da3eed75969621f562887734313568d0852939dd6d91492bf56e30d94&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Subtype ë³„ ê°ì„±ì œ ì•½ë¬¼ ë°˜ì‘ì„± í™•ì¸

- Methylphenidate Derivative(MPH), Amphetamine (AMPH)
- ë‘ ì•½ë¬¼ì€ ADHDì˜ 1ì°¨ ì¹˜ë£Œì œ

**ë¶„ì„ ì§€í‘œ**

- `ADHD severity` : change of CBCL-ADHD t-score at DSM-5 scale, Î”CBCL-ADHD
- `Disease symptoms` : change of KSADS-COMP ADHD diagnostic symptom number, Î”KSADS

<span class="notion-red">_â†’ Baselineì—ì„œì˜ severityì™€ symptomì´ ìœ ì‚¬í–ˆìŒì—ë„ ê°ì„±ì œ íˆ¬ì•½ í›„ subtype ë³„ íšŒë³µ ì •ë„ëŠ” ì°¨ì´ ë³´ì„(High-developed ì˜ ê²½ìš° ì•½ë¬¼ ë°˜ì‘ ì•½í•¨, under-developedê°€ ë‚˜ì€ íšŒë³µë¥  ë³´ì„)_</span>


<span class="notion-red">_â†’ ì•½ë¬¼ ë¯¸íˆ¬ì—¬êµ°ì— ëŒ€í•´ subtype ë³„ë¡œ ìœ ì˜ë¯¸í•œ ì°¨ì´ ì—†ìŒ_</span>


---



#### Distinct transcriptomic signatures among the subtypes


**RNA expression data(AHBA transcriptome dataset)ì™€ CT T-mapì˜ correlation ë¶„ì„**

- Subtypeì˜ genetic basis ì¡°ì‚¬
- Bonferroni correction ì‚¬ìš©
- `Under-developed` : 1063/1335 (pos/neg)
- `Over-developed` : 1120/713
- `Mixed` : 315/534

**Subtype ë³„ ìƒìœ„ 300ê°œ gene ì´ìš©í•´ Enrichment ë¶„ì„**

- Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (KEGG) database ê¸°ë°˜
- FDR correction ì‚¬ìš©
- `Underâ€‘developed`
	- GO/KEGGì—ì„œ ë‹¤ìˆ˜ì˜ ì‹ ê²½ì „ë‹¬ ê´€ë ¨ í•­(term) í’ë¶€
	- GABAergic synapse, dopaminergic synapse, glutamatergic synapse, regulation of dopamine secretion ë“±.

	_â†’ í•´ë‹¹ subtypeì˜ CT íŒ¨í„´ê³¼ ì¼ì¹˜í•˜ëŠ” ìœ ì „ìë“¤ì´ ë„íŒŒë¯¼Â·GABAÂ·ê¸€ë£¨íƒì‚° ê²½ë¡œì™€ ë°€ì ‘í•˜ê²Œ ì—°ê²°ë˜ì–´ ìˆì–´, neurotransmitter ë¶ˆê· í˜•(ë˜ëŠ” ë³€ì¡°)ì´ êµ¬ì¡°ì  ì°¨ì´ë¥¼ ë°˜ì˜í•  ê°€ëŠ¥ì„± ì¡´ì¬_

- `Mixed`
	- GABAergic ë° glutamatergic ê´€ë ¨ í•­ì´ í’ë¶€

	_â†’ ì‹ ê²½ì „ë‹¬ì²´ê³„ ê´€ë ¨ ê¸°ì „ì´ ê´€ì—¬ëœë‹¤ëŠ” ì ì—ì„œ underâ€‘developedì™€ ìœ ì‚¬_

- `Overâ€‘developed`
	- ì‹ ê²½ì „ë‹¬ ê´€ë ¨ë³´ë‹¤ëŠ” ëŒ€ì‚¬/ì¸ìŠë¦° ê´€ë ¨ í•­(e.g. regulation of insulin secretion)ì´ ìœ ì˜í•˜ê²Œ í’ë¶€

	_â†’ Neurotransmitter ê²½ë¡œë³´ë‹¤ëŠ” ëŒ€ì‚¬ì  (insulin/ë¹„ë§Œ ê´€ë ¨) ìœ ì „ì  ê¸°ì§ˆê³¼ ì—°ê´€ë  ìˆ˜ ìˆê³ , ì´ëŠ” ì„ìƒì ìœ¼ë¡œ ë¹„ë§ŒÂ·ëŒ€ì‚¬ ì—°ê´€ì„±ìœ¼ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆìŒ_


_â†’ Subtype ê°„ ëšœë ·í•œ ìœ ì „ì  íŠ¹ì„± ì¡´ì¬_


_â†’ Under-develoepd/Mixed subtypeì˜ ê²½ìš° neurotransmitter ê´€ë ¨ ìœ ì „ì  ë¿Œë¦¬ ê°€ì§_


_â†’ Over-developedì˜ ê²½ìš° comorbid(insulin) ìœ ì „ì  ë¿Œë¦¬ ê°€ì§_


**ADHD ê´€ë ¨ ìœ ì „ì ë¶„ì„ (TWAS ê¸°ë°˜ í›„ë³´)**


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/b9862833-4ef6-427e-a2a2-58f10552bfbe/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB46666ZOA5GQ%2F20260201%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260201T041708Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDwVa7jq6WgAwh%2FulpS2Pe5srACBRxhCmgfxdHD%2BpEZuAIhAMLYaYPMLXCGH42PAfqjuJ8vcQuaE%2Bj%2BDwxe6v%2Bkx%2BCjKogECMT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNjM3NDIzMTgzODA1IgzV7hATj1m9vrvzzQgq3AOM%2Bz%2BQp9sBw5pZeElxqRx44prKCTRvI1k6l61TE8EJ7K0Tb2yyV2nSfyn4Dfgkb52sbTpV5Ucw0j2iJgFlL%2F0rNrOVeOMoBATEabEPb8P9yHEshXcAiFusfE819Ij%2FV4D1u3xHDuYcMuxrES%2FSDCpyp1VG8UzPLtFAkILx9FKqA1c9ueWG8CB6QQ5OPEyZP08jhlqvi9rSUzEZTiwMGa1b0U%2FU%2BL7VN8uy7BOD7Muehvm1oHiZ968sj%2FpVLeWgVHGPyAl3P211lbED%2FdI18F%2BgXr%2BDrXYkA6IX47pBS9mewEQKAY4SXt6BMlagLTOdkG8DNXHp7J11rV32DzvxcwLlw0MbsIdzUlE9yiqDmtamDtzl3URayPsd08Hihj1pTyE68EYGB9tBGUZbK%2BN7yOh%2FWPaqLeWT30xgIeRe6AfrHoMKZj4jsrKCICJkY4TI3cbTHtL57b4maANdUy3BU%2FC7P4iYQrMnDsL%2FexbCybmBYqf567oGPEGVrYcZBv27H7wtyCaw30jlP4Cbcrm%2BbmivdnadIDKOR%2BboVZKgpQmaK6U4RXfRS1HPP%2Fk%2Bx%2B3%2B3qcuKY%2BE7WyLZa%2BSZZ%2FUJK9IC4mcfOgQLtcZ5q7mf2%2FLeskfJk1hwF382DPkNDCHg%2FvLBjqkARk1v%2BkN665IbIAXS6pfY6uhrPy5mqJ6R6LQx5oWZRzUboraxhPHDzndus3BiX8kUyM1Z1I64IlYiIXVO9CKE3GOBp0F1bqXIlU2qjYtpELUo5tzdwO0c1wGwWoxUb8Old%2FAAWlfto3bJ0UoPUm4mHa5PuZe%2FYEgkf76XYEhNHCX0dGAcTUj%2Fl8D%2BRt8qrJB6HuVIWOcDreAeSi29dgu1wa0%2BMte&X-Amz-Signature=a8c70bd7f62b425fc395612a51dd32eed5f64c26ce1815e8e0485414ec75ed9e&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)

- **(a)** TWASë¡œ ë³´ê³ ëœ 8ê°œ ìœ ì „ì ì¤‘ AHBAì— ë‚¨ì•„ìˆë˜ 5ê°œ ìœ ì „ìì— ëŒ€í•´ permutation(1000ë²ˆ)ì„ ì‚¬ìš©í•´ subtypeê³¼ì˜ correlation í‰ê°€
	- ë°œê²¬ëœ subtypeâ€‘ê´€ë ¨ ìœ ì „ì(4ê°œ): CCDC24, ELOVL1, TIE1, MED8
	- `Underâ€‘developed`: CCDC24, MED8ì™€ ì–‘ì˜ ìƒê´€; TIE1ì™€ ìŒì˜ ìƒê´€
	- `Overâ€‘developed`: CCDC24, MED8ì™€ ìŒì˜ ìƒê´€
	- `Mixed`: ELOVL1, TIE1ì™€ ì–‘ì˜ ìƒê´€
- **(b)-(d)** 5ê°œ ìœ ì „ìì˜ 2ê°œ PC ì´ìš©í•´ ì¶”ê°€ ë¶„ì„
	- ROI ë³„ Gene expressionìœ¼ë¡œë§Œ PC ê³„ì‚°, ìƒìœ„ 2ê°œì— ëŒ€í•´ ë¶„ì„
	- ROI ë³„ CTê°’ê³¼ PCì˜ ì‚°ì ë„ êµ¬í•¨

<span class="notion-red">_â†’ ë™ì¼í•œ ADHDâ€‘ê´€ë ¨ í›„ë³´ ìœ ì „ìì¡°ì°¨ subtypeë§ˆë‹¤ spatial correlation ë‹¬ë¼ ìœ ì „ì  ê¸°ì§ˆì˜ ì´ì§ˆì„± ì‹œì‚¬._</span>


---



#### Stronger dopamine upregulation in under-developed and mixed subtypes


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/b23fd3d2-7c82-4f9c-9578-378d805f0b5f/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB46666ZOA5GQ%2F20260201%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260201T041708Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDwVa7jq6WgAwh%2FulpS2Pe5srACBRxhCmgfxdHD%2BpEZuAIhAMLYaYPMLXCGH42PAfqjuJ8vcQuaE%2Bj%2BDwxe6v%2Bkx%2BCjKogECMT%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNjM3NDIzMTgzODA1IgzV7hATj1m9vrvzzQgq3AOM%2Bz%2BQp9sBw5pZeElxqRx44prKCTRvI1k6l61TE8EJ7K0Tb2yyV2nSfyn4Dfgkb52sbTpV5Ucw0j2iJgFlL%2F0rNrOVeOMoBATEabEPb8P9yHEshXcAiFusfE819Ij%2FV4D1u3xHDuYcMuxrES%2FSDCpyp1VG8UzPLtFAkILx9FKqA1c9ueWG8CB6QQ5OPEyZP08jhlqvi9rSUzEZTiwMGa1b0U%2FU%2BL7VN8uy7BOD7Muehvm1oHiZ968sj%2FpVLeWgVHGPyAl3P211lbED%2FdI18F%2BgXr%2BDrXYkA6IX47pBS9mewEQKAY4SXt6BMlagLTOdkG8DNXHp7J11rV32DzvxcwLlw0MbsIdzUlE9yiqDmtamDtzl3URayPsd08Hihj1pTyE68EYGB9tBGUZbK%2BN7yOh%2FWPaqLeWT30xgIeRe6AfrHoMKZj4jsrKCICJkY4TI3cbTHtL57b4maANdUy3BU%2FC7P4iYQrMnDsL%2FexbCybmBYqf567oGPEGVrYcZBv27H7wtyCaw30jlP4Cbcrm%2BbmivdnadIDKOR%2BboVZKgpQmaK6U4RXfRS1HPP%2Fk%2Bx%2B3%2B3qcuKY%2BE7WyLZa%2BSZZ%2FUJK9IC4mcfOgQLtcZ5q7mf2%2FLeskfJk1hwF382DPkNDCHg%2FvLBjqkARk1v%2BkN665IbIAXS6pfY6uhrPy5mqJ6R6LQx5oWZRzUboraxhPHDzndus3BiX8kUyM1Z1I64IlYiIXVO9CKE3GOBp0F1bqXIlU2qjYtpELUo5tzdwO0c1wGwWoxUb8Old%2FAAWlfto3bJ0UoPUm4mHa5PuZe%2FYEgkf76XYEhNHCX0dGAcTUj%2Fl8D%2BRt8qrJB6HuVIWOcDreAeSi29dgu1wa0%2BMte&X-Amz-Signature=319bfbbecbfecf6c0280f233052ebd18069ac98d87bb61be1ba39da36bc6460d&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Neurotransmitter ê´€ë ¨ pathwayê°€ ì¡´ì¬í•œë‹¤ëŠ” ìœ ì „ì  ë°œê²¬ì— ê¸°ë°˜í•´ neurotransmitter profile ì¡°ì‚¬

- Under-developed/mixed subtype ê³¼ ê´€ë ¨
- ABA-ergic synapse, dopaminergic synapse, glutamatergic synapse
- `Under-developed` : Dopamin receptor D1/D2, DAT, GluR5ì™€ ì–‘ì˜ ìƒê´€ê´€ê³„ (r = 0.555, 0.470, 0.566, r = 0.382, P\_{permu}<0.001)
- `Over-developed` : D1, DAT, GluR5ì™€ ìŒì˜ ìƒê´€ê´€ê³„ (r = âˆ’0.316, âˆ’0.407, âˆ’0.181, P\_{permu}<0.001, <0.001, 0.015)
- `Mixed` : D1, DAT, GluR5ì™€ ìŒì˜ ìƒê´€ê´€ê³„( r = âˆ’0.269, âˆ’0.652, âˆ’0.303, P\_{permu} < 0.001)

<span class="notion-red">_â†’ Over-developed/MixedëŠ” ìœ ì‚¬í•œ ìŒì˜ ìƒê´€ê´€ê³„ ë³´ì„_</span>


<span class="notion-red">_â†’ Under-developed/Mixed subtypeì€ Over-developed ë³´ë‹¤ ë” í° ìƒê´€ê´€ê³„ í¬ê¸°ë¥¼ ë³´ì„_</span>


---


---



## Discussion

- Semi-supervised learning method(Smile-GAN)ì„ ì´ìš©í•œ ADHDì˜ heterogenity ë¶„ì„
- ëšœë ·í•œ Cortical thickness profile ê°€ì§€ëŠ” ì„¸ ê°€ì§€ subtype ë¶„ë¥˜
- Under-developed subtypeì€ ê°€ì¥ ë‚®ì€ cognitive scoreë¥¼ ë³´ì´ë©°, í™˜ê²½ì  ìŠ¤íŠ¸ë ˆìŠ¤(ë‚®ì€ ê°€ê³„ ì†Œë“/ë¶€ëª¨ êµìœ¡ ìˆ˜ì¤€)ì™€ ê´€ë ¨ ìˆì„ ìˆ˜ ìˆìŒ
- Over-developed subtypeì€ stimulant medication ë°˜ì‘ì´ ê°€ì¥ ì¢‹ì§€ ì•Šì•˜ê³ , ADHDì˜ ë¹„ì •í˜•ì  íŠ¹ì§•ê³¼ ê´€ë ¨ ìœ ì „ì/ì‹ ê²½ ì „ë‹¬ ë¬¼ì§ˆ ê²½ë¡œì™€ì˜ ë‚®ì€ ìƒê´€ê´€ê³„ì™€ ì—°ê´€ì´ ìˆì„ ìˆ˜ ìˆìŒ

---


---



## Limitations

- AHBAëŠ” ì„±ì¸ HCì˜ ì†Œìˆ˜ sample data â†’ ì—°ë ¹, ì§ˆí™˜ ì°¨ì´ ì¡´ì¬í•¨
